Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Geoffrey Manley, MD PhD
Headshot of Geoffrey Manley
Geoffrey Manley

Description

Summary

The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drugs listed below are approved by the U.S. Food and Drug Administration (FDA) but are being used "off-label" in this study. This means that the drugs are not currently approved to treat TBI.

Keywords

Traumatic Brain Injury, Brain Injuries, Traumatic Brain Injuries, Wounds and Injuries, Minocycline, Candesartan, Candesartan cilexetil, Atorvastatin, Calcium, Atorvastatin Calcium, Minocycline Hydrochloride

Eligibility

Location

  • UCSF
    San Francisco California 94110 United States

Lead Scientist at UCSF

  • Geoffrey Manley, MD PhD
    Dr. Manley is Chief of Neurosurgery at Zuckerberg San Francisco General Hospital and Professor and Vice Chairman of Neurological Surgery at UCSF. He is a trauma neurosurgeon and Co-Director of the Brain and Spinal Injury Center. Dr. Manley's research interests range from molecular aspects of traumatic brain injury (TBI) to the clinical care of TBI victims.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
Links
Related Info Related Info #2 Related Info #3
ID
NCT05826912
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 672 study participants
Last Updated